Drug Trial Radar · NCT00844298
Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Last checked: Nov 20, 2026Latest source record: Sep 7, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
91
Actual
Start
Jan 2009
Primary completion
Jun 2012
Study completion Jul 2014
Sponsor
- Lead sponsor
- Asan Medical CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Feb 16, 2009
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 15 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
RATIONALE: Nilotinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving nilotinib together with combination chemotherapy may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving nilotinib together with combination chemotherapy works in treating patients with newly diagnosed acute lymphoblastic leukemia.
Conditions
- Leukemia
Interventions
Nilotinib+mVPDDrug
1. Induction: * Daunorubicin 90 mg/m2/day by continuous iv infusion (d1-3) * Vincristine 2 mg iv push (d1, 8, 15, 22) * Prednisolone 60 mg/m2/day po (d1-28) * Nilotinib 400mg bid/d (d8-) 2. Consolidation A (cycle1) * Daunorubicin 45 mg/m2/day by continuous iv (d1, 2) * Vincristine 2 mg iv (d1, 8) * Prednisolone 60 mg/m2/day po (d1-14) * Nilotinib 400mg bid/d 3. Consolidation B (cycles 2\&4) * Cytarabine 2,000 mg/m2/day iv over 2 hours (d1-4) * Etoposide 150 mg/m2/day iv over 3 hours (d1-4) * Nilotinib 400mg bid/d 4. Consolidation C (cycles 3\&5) * Methotrexate 220 mg/m2 iv bolus, then 60mg/m2/h for 36 hours (d1-2, 15-16) * Leucovorin followed immediately by 50 mg/m2 iv every 6hrs for three doses, * Nilotinib 400mg bid/d 5. Maintenance ◦Nilotinib 400mg bid/d (during 2 years, for patients without alloHCT) 6. Consider alloHCT
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of Patients Achieving Hematologic and Molecular Complete Remission (CR) After Induction TherapyTime frame: 1 month
Locations
16 sites in 1 country. Site status is shown where the registry gives one.
Daegu Fatima Hospital
Daegu, South Korea
Kyungpook National University Hospital
Daegu, South Korea
Yeungnam University Medical Center
Daegu, South Korea
Daegu Catholic University Hospital
Daegu, South Korea
National Cancer Center - Korea
Goyang, South Korea
Chonnam National University Hwasun Hospital
Jeollanam-do, South Korea
Gyeongsang National University Hospital
Jinju, South Korea
Pusan National University Hospital
Pusan, South Korea
Inje University Seoul Paik Hospital
Seoul, South Korea
Seoul National University Hospital
Seoul, South Korea
Kyung Hee University Hospital
Seoul, South Korea
Samsung Medical Center
Seoul, South Korea
Asan Medical Center - University of Ulsan College of Medicine
Seoul, South Korea
Konkuk University Medical Center
Seoul, South Korea
Ajou University Hospital
Suwon, South Korea
Ulsan University Hospital
Ulsan, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.